Caplacizumab is a nanobody drug used for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, manufactured by Sanofi (France). It has not yet been launched in China and is not covered by China's national medical insurance.
Latest Price of Caplacizumab in 2025
As a specific drug for treating aTTP, the price of caplacizumab is a key concern for patients.
International Market Pricing
The official price of the original drug Cablivi (manufactured by Sanofi, France) is USD 4,197 per box (11mg/vial). This price reflects the R&D costs of the nanobody drug and the complexity of its production process. The above price is for reference only.
Factors Affecting the Price
Patent protection status: This is the main reason for maintaining the high price. Sanofi’s patent protection for this drug will last until 2026.
Special production process: The nanobody technology used in production, combined with the relatively small patient population, leads to high amortized costs.
Future trends: With the progress of biosimilar drug R&D, the price may decrease in the next 2-3 years.
Procurement Channels for Caplacizumab
Since caplacizumab has not been launched in China, patients need to obtain it through special channels.
Cross-Border Medical Cooperation
Some domestic hospitals have cooperative channels with international medical institutions, which can assist patients in purchasing the drug from formal pharmacies in Europe. This method requires the provision of complete medical records and a prescription.
Direct Mailing from Authorized Pharmacies
Sanofi has authorized pharmacies in some countries to provide international direct mailing services. Patients need to check the list of authorized pharmacies through the official website, and after submitting the prescription and identification documents, the pharmacy can deliver the drug directly via professional logistics with full-process temperature monitoring.
Overseas Medical Treatment and Drug Purchase
For patients who have the conditions to travel to Europe, they can purchase the drug directly from hospital pharmacies in approved countries such as France and Germany. They need to carry a prescription issued by a local doctor; some countries require the provision of medical insurance certificates or tourist visas.
Storage Methods for Caplacizumab
Proper storage is crucial for the efficacy and safety of the drug. As a biological agent, caplacizumab has strict requirements for storage conditions.
Storage of Unopened Drugs
The original packaging must be refrigerated in a refrigerator at 2-8°C, avoiding direct contact with the inner wall of the refrigerator or the freezer compartment.
Store in the original carton to protect from light; freezing is not allowed.
Under special circumstances, it can be stored at room temperature below 30°C for no more than 2 months, but once taken out of the refrigerator, it cannot be put back.
Handling of Reconstituted Solutions
The reconstituted solution should be used immediately. If short-term storage is necessary, it must be stored at 2-8°C for no more than 4 hours.
Visually inspect the solution before use; if turbidity or precipitation occurs, it must be discarded.
Any remaining liquid in the syringe cannot be retained for reuse.
Specifications for Travel Transportation
For short-distance transportation, a dedicated medical cooler bag (maintaining 2-8°C) equipped with a temperature recorder must be used.
For long-distance transportation, professional transport boxes must be used, with phase-change materials to maintain the temperature. The entire process must be monitored, and temperature records must be retained.
It is recommended to establish a drug storage log, regularly check and record the refrigerator temperature, and avoid storing the drug with other medications to prevent cross-contamination. Expired drugs must be disposed of in accordance with medical waste regulations.
